ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Successful Use of Tedizolid for the Treatment of Nocardiosis in Transplant Recipients

R. Odrobina1, B. Tritle2, C. A.Gomez1

1Division of Infectious Diseases, University of Utah, Salt Lake City, UT, 2Department of Pharmacy, University of Utah, Salt Lake City, UT

Meeting: 2020 American Transplant Congress

Abstract number: D-160

Keywords: Adverse effects, Bacterial infection, Bone marrow transplantation, Infection

Session Information

Session Name: Poster Session D: All Infections (Excluding Kidney & Viral Hepatitis)

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Nocardiosis is an opportunistic infection occasionally seen after solid organ (SOT) and hematopoietic stem-cell transplantation. Treatment is challenging due to the limited number of oral agents, drug intolerance, organism resistance, toxicity and need for prolonged therapy.

*Methods: Linezolid (LZD) and tedizolid (TZD) both have demonstrated excellent in vitro activity against Nocardia species. However, long-term use of LZD is often prohibited by high rates of hematological and mitochondrial toxicity (ie, myelosuppression, lactic acidosis, and peripheral neuropathy). Conversely, long-term therapy with TZD may be better tolerated, but evidence is scarce. Herein, we report the successful use of long-term TZD as the cornerstone of nocardiosis therapy in four transplant patients. (Table 1).

*Results: A 51-year-old woman underwent a deceased-donor kidney transplantation (KT). Six months later she developed fever, chills, and cough. Imaging showed diffuse, patchy ground-glass opacities with focal consolidation of the left upper lobe. Blood and sputum cultures grew Nocardia nova. She was started on trimethoprim-sulfamethoxazole (TMP-SMX) and LZD. Due to intolerance, she was switched to azithromycin and TZD which she has tolerated well for 11 months into a planned year-long therapy. A 54-year-old male underwent a living, unrelated-donor KT. 26 months after transplant he developed a headache, confusion, and altered gait. Imaging showed a new left occipital brain abscess. Intraoperative cultures grew Nocardia paucivorans. He was initially treated with ceftriaxone and TMP-SMX. Due to hyperkalemia and renal failure, he continued ceftriaxone with TZD with a plan for 1 year of therapy. A 54-year-old male underwent an allogeneic stem cell transplant (SCT). Seven months later he developed a large pleural effusion with cultures positive for Nocardia veterana. He received empiric TMP-SMX and LZD. Due to side effects, his antimicrobials were changed, and he successfully completed treatment with TMP-SMX and TZD. A 60-year-old male underwent allogeneic SCT. Eight months after transplantation he developed fever and cough. Chest imaging revealed numerous pulmonary nodules. Pulmonary and blood cultures grew Nocardia cyriacigeorgica. Initial broad-spectrum antibiotics were changed to TMP-SMX and TZD which he has continued with clinical improvement.

*Conclusions: All patients responded to therapy appropriately and tolerated TZD well. We postulate a potential role of TZD in treatment of nocardiosis in transplant recipients.

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Odrobina R, Tritle B, AGomez C. Successful Use of Tedizolid for the Treatment of Nocardiosis in Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/successful-use-of-tedizolid-for-the-treatment-of-nocardiosis-in-transplant-recipients/. Accessed May 17, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences